Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688393's 5-Year Yield-on-Cost % is ranked worse than 87.03% of 316
companies
in the Medical Devices & Instruments industry
Industry Median: 2.425
vs SHSE:688393: 0.50
Guangzhou LBP Medicine Science & Technology Co (SHSE:688393) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Guangzhou LBP Medicine Science & Technology Co 5-Year Yield-on-Cost % Related Terms
SHSE:688393 vs ISRG, BDX, RMD: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, Guangzhou LBP Medicine Science & Technology Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou LBP Medicine Science & Technology Co 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
Guangzhou LBP Medicine Science & Technology Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Guangzhou LBP Medicine Science & Technology Co (SHSE:688393) has a 5-Year Yield-on-Cost % of 0.50 as of Sep. 02, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Guangzhou LBP Medicine Science & Technology Co and its competitors. This is 38% below median its historical median of 0.81. Over the past decade, Guangzhou LBP Medicine Science & Technology Co's 5-Year Yield-on-Cost % has ranged from 0.30 to 1.37. According to the industry distribution chart, Guangzhou LBP Medicine Science & Technology Co ranks #275 out of 316 companies in the Medical Devices & Instruments industry, placing it in the top 87%.
Is Guangzhou LBP Medicine Science & Technology Co's 5-Year Yield-on-Cost % too high?
Guangzhou LBP Medicine Science & Technology Co's current 5-Year Yield-on-Cost % of 0.50 is 38% below median its 10-year median of 0.81. Over the past 10 years, this metric has ranged from a low of 0.30 to a high of 1.37. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.43. Guangzhou LBP Medicine Science & Technology Co's value of 0.50 is 79.4% below this industry median. Based on the distribution chart, Guangzhou LBP Medicine Science & Technology Co ranks #275 out of 316 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Guangzhou LBP Medicine Science & Technology Co has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou LBP Medicine Science & Technology Co's 5-Year Yield-on-Cost % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Guangzhou LBP Medicine Science & Technology Co ranks #275 out of 316 companies for 5-Year Yield-on-Cost %. This places Guangzhou LBP Medicine Science & Technology Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.43. Guangzhou LBP Medicine Science & Technology Co's value of 0.50 is 79.4% below this benchmark. Historically, Guangzhou LBP Medicine Science & Technology Co's own 5-Year Yield-on-Cost % has ranged from 0.30 to 1.37 over the past decade. While the company's 10-year median is 0.81 vs. the industry median of 2.43, Guangzhou LBP Medicine Science & Technology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.43, based on 316 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guangzhou LBP Medicine Science & Technology Co's current 5-Year Yield-on-Cost % of 0.50 is 79.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Guangzhou LBP Medicine Science & Technology Co and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangzhou LBP Medicine Science & Technology Co's current 5-Year Yield-on-Cost % is 0.50, which is 38% below median its own 10-year median of 0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou LBP Medicine Science & Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou LBP Medicine Science & Technology Co (SHSE:688393) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥32.08, compared to a current price of ¥20.69 — trading 35.5% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.50, which is 38% below median its 10-year median of 0.81 and 79.4% below the Medical Devices & Instruments industry median of 2.43. Guangzhou LBP Medicine Science & Technology Co's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Guangzhou LBP Medicine Science & Technology Co (SHSE:688393), the current 5-Year Yield-on-Cost % is 0.50 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou LBP Medicine Science & Technology Co (SHSE:688393) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou LBP Medicine Science & Technology Co stock appears to be undervalued.
The current stock price of ¥20.69 is trading 35.5% below its estimated GF Value™ of ¥32.08.
GuruFocus considers Guangzhou LBP Medicine Science & Technology Co to be Significantly Undervalued.
Key valuation signals for SHSE:688393:
5-Year Yield-on-Cost %: 0.50 (38% below median its 10-year median of 0.81)
GF Value™: ¥32.08 vs. price of ¥20.69 (35.5% below fair value)
Industry Position: 79.4% below the Medical Devices & Instruments median (#275 of 316)
No single metric tells the full story. See the SHSE:688393 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangzhou LBP Medicine Science & Technology Co Ltd is engaged in production and sales of in vitro diagnostic reagents and instruments. The company's products include Fluorescence in situ hybridization (FISH) series; Immunohistochemistry (IHC) series; Liquid - based cytology (LBP) series; PCR series; and medical laboratory.
59GF Score
Get the complete analysis for SHSE:688393
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688393 has been successfully added to your 
